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Abstract 
Background: Cells respond to DNA damage by activating the phosphatidylinositol‑3 kinase‑related kinases, p53 and 
other pathways to promote cell cycle arrest, apoptosis, and/or DNA repair. Here we report that protein palmitoyla‑
tion, a modification carried out by protein acyltransferases with zinc‑finger and Asp‑His‑His‑Cys domains (zDHHC), is 
required for proper DNA damage responses.
Results: Inhibition of protein palmitoylation compromised DNA damage‑induced activation of Atm, induction and 
activation of p53, cell cycle arrest at G2/M phase, and DNA damage foci assembly/disassembly in primary mouse 
embryonic fibroblasts. Furthermore, knockout of zDHHC16, a palmitoyltransferase gene identified as an interacting 
protein for c‑Abl, a non‑receptor tyrosine kinase involved in DNA damage response, reproduced most of the defects 
in DNA damage responses produced by the inhibition of protein palmitoylation.
Conclusions: Our results revealed critical roles for protein palmitoylation and palmitoyltransferase zDHHC16 in early 
stages of DNA damage responses and in the regulation of Atm activation.
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Background
Protein palmitoylation, or protein S-acylation, is a post-
translational modification that adds a palmitate moiety to 
specific Cys residues by a family of proteins named pro-
tein acyltransferases (PATs) [1–4]. All PAT proteins con-
tain a DHHC domain, a 51-amino acid Cys-rich domain 
with a highly conserved Asp-His-His-Cys sequence. The 
other regions of the PATs are variable. The zDHHC genes 
are numerically named zDHHC1-24 [4]. Unlike N-myris-
toylation or C-prenylation, S-acylation can be reversed 
by protein palmitoyl thioesterases and acyl protein thi-
oesterases, making it a reversible lipid modification [5].
A number of cellular proteins have been reported to 
be palmitoylated, which are involved in different cellular 
activities such as cell signaling, protein trafficking, and 
cell adhesion [6–8]. Most of the palmitoylated proteins 
are membrane or peripheral membrane proteins, yet 
it is noteworthy that some non-membrane associated 
proteins are also palmitoylated. The importance of pro-
tein palmitoylation is manifested in zDHHC deficient 
mouse models. For example, mice deficient for zDHHC8 
gene have increased risk of schizophrenia [9]. Mice with 
zDHHC13 mutation show alopecia, osteoporosis, and 
amyloidosis [10]. A spontaneous mutation of zDHHC21 
gene in mice leads to hair loss due to defective epidermal 
homeostasis and hair follicle differentiation [11]. We have 
recently reported that mice null of zDHHC16 gene are 
neonatal lethal with severe heart and eye defects [12].
Recent studies have also implicated protein palmitoyla-
tion and PATs in cancer development. The expression of 
some zDHHC genes was found altered in various can-
cer tissues [13, 14]. Yet how PATs participate in cancer 
development remains unclear. Cancer development is 
driven by the accumulation of gene mutations, especially 
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loss-of-function mutations of tumor suppressors and 
gain-of-function mutations of oncoproteins [15]. How-
ever, cell has a protective system, the DNA damage 
response (DDR), to monitor DNA damage and to repair 
the damage or eliminate the cells with irreparable DNA 
lesions [16–18]. Upon DNA damage, the cell acti-
vates the phosphatidylinositol-3 kinase-related kinases 
(PIKKs) such as Atm and Atr at the DNA break sites. A 
large number of proteins, including γH2AX and BRCT 
domain-containing proteins such as Brca1, TopBP1, and 
Mdc1 are recruited to the DNA break sites, forming tran-
sient nuclear structures named DNA damage foci, which 
are thought to be the centers for signal propagation and 
DNA repair [19–21]. Atm phosphorylates many sub-
strates including Smad1, p53 and Chk2, which eventually 
cause cell cycle arrest and/or apoptosis [22–25]. Thus, a 
functional DDR is critical for maintaining genome integ-
rity and preventing tumor development. On the other 
hand, tumor cells usually have disrupted DDR [18]. Up 
to date, it is not known whether protein palmitoylation 
plays a role in DNA damage response.
In the present study, we investigated the roles of pro-
tein palmitoylation in DNA damage response. We found 
defective DDR including Atm activation, p53 induction 
and activation, cell cycle arrest at G2/M phase, and assem-
bly/disassembly of DNA damage foci in primary mouse 
embryonic fibroblasts (MEFs) in the presence of 2-bromo-
palmitate (2BP), a general PAT inhibitor [26–28]. These 
results were also observed in MEFs deficient of zDHHC16 
gene which encodes a palmitoyltransferase. These findings, 
for the first time, unravel an important function of PATs, 
in particular zDHHC16, in DNA damage response and in 
Atm activation, and provide a possible explanation on how 
zDHHC proteins participate in tumorigenesis.
Methods
Mice and cells
Mice were housed, bred and used in a specific pathogen 
free (SPF) animal facility at the Bio-X Institute, Shang-
hai Jiao Tong University. Specifically, no more than five 
adult mice were housed in one individually ventilated 
cage with sterilized food, water and woodchip bedding. 
The animal facility was maintained by professional care 
takers 7 days a week on a 12 h light/12 h dark cycle. The 
study was approved by the Institutional Animal Care 
and Use Committee of Shanghai Jiao Tong University 
[SYXK(SH)2011-0112]. Timed pregnant female mice 
were euthanized on embryonic E13.5 by intraperitoneal 
injection of over-dosed pentobarbital. The time of preg-
nancy was determined by visual examination of the vagi-
nal plug in the early morning. Embryos were dissected 
and fibroblasts were isolated as described previously [24]. 
The generation and characterization of the zDHHC16 
knockout mice were described in detail in our previous 
paper [12]. One pregnant C57Bl/6 wildtype and three 
zDHHC16 knockout mice were used to obtain all MEFs 
used in this study. The knockout mice were in mixed 
C57BL/6 and CBA background. All efforts were made to 
minimize the suffering of mice.
Cells were cultured in Dulbecco’s modified Eagle’s 
medium (Thermo Fisher Scientific Inc./Life Technolo-
gies, Grand island, NY, USA) containing 10  % fetal calf 
serum (Excell Biology Inc., Shanghai, China). They were 
plated at 106 cells per 6  cm dish and allowed to grow 
overnight before any treatment. To inhibit cellular PAT 
activity, 2BP (2-bromopalmitate, Sigma-Aldrich, China) 
was used at 50 or 100 μM for 24 h as indicated. To induce 
DNA damage response, doxorubicin (Dox) (Selleck 
Chemicals, Houston, TX, USA) was used at 1 μM for dif-
ferent time as indicated in each experiment.
Western blot analysis
Standard RIPA buffer containing 1 mM PMSF, 1 μg/mL 
aprotonin, leupeptin, and pepstatin was used for protein 
extraction. Protein concentration was measured using 
Bio-Rad DC protein assay kit (Bio-Rad Inc., Hercules, 
CA, USA). Western blot analysis was carried out accord-
ing to the standard procedure. We used polyvinylidene 
fluoride membrane for protein transfer, and 5  % non-
fat dried milk in PBS as the blocking agent. All primary 
antibodies were incubated overnight at 4  °C. Chemilu-
minescent detection method (ECL kit, GE Healthcare, 
Buckinghamshire, UK) coupled with Bio-Rad ChemiDoc 
XRS imaging system were used for the detection, visu-
alization and quantitation of the proteins. All primary 
antibodies were purchased from cell signaling technology 
and used according to the provider’s instruction except 
for the following: anti-Atm antibody was purchased from 
ECM Biosciences (AM3611), anti-p-Atm antibody was 
purchased from Millipore (05-740) and anti-β-Actin was 
purchased from Santa Cruz (SC81178).
Flow cytometry
Cells were digested with 0.25 % trypsin, washed with cold 
PBS and fixed in 70  % ethanol at −20  °C overnight. At 
the next day, cells were washed with cold PBS again and 
incubated in PBS containing 50 μg/mL propidium iodide 
(PI) and 100  μg/mL RNase A for 40  min in the dark at 
room temperature. The fixed and labeled cells were ana-
lyzed with Becton–Dickinson FACSCalibur (BD Biosci-
ence, San Jose, CA, USA).
In vitro analysis of DNA damage foci positive for γH2AX, 
TopBP1, and BRCA1
Cells cultured on glass slides were fixed in 4  % para-
formaldehyde/PBS for 30  min followed by 0.1  % 
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TritonX-100/PBS incubation for 40  min at room tem-
perature. The standard immunostaining procedure 
was used. Specifically, 10 % goat serum was used as the 
blocking agent. Primary antibody incubation was car-
ried at 4 °C overnight. Anti-p-H2AX antibody was pur-
chased from Millipore (05-636), anti-TopBP1 antibody 
was purchased from BD Bioscience (611875), and anti-
Brca1 antibody was purchased from Abcam (ab191042).
Reverse transcription (RT)‑polymerase chain reaction (PCR)
Trizol reagent (Invitrogen, Thermo Fisher Scientific, 
Grand island, NY, USA) was used to extract whole RNA 
and reverse transcribed using SuperScript III reverse tran-
scriptase and random primer (Invitrogen, ThermoFisher 
Scientific, USA). Relative quantitative PCR was performed 
using the primers listed in Table 1 and the FastStart Uni-
versal SYBR Green Master from Roche (Roche Diagnostic 
GmbH, Mannheim, Germany). β-actin and glyceraldehyde 
3-phosphate (GAPDH) were used as internal controls.
Statistical analysis
Each experiment was repeated at least three times or 
using cells isolated from three mutant and control mice. 
The results were analyzed using analysis of variance 
(ANOVA) with Fisher’s LSD (least significant differ-
ence) test when more than two groups were compared 
or unpaired t test when two groups were compared 
(SPSS version 18). p Value of equal or less than 0.05 was 
accepted as statistically significant.
Results
Most of the zDHHC genes are expressed in MEFs
We chose to use primary MEFs for this study as most 
of the immortal cell lines show disrupted DNA dam-
age response [18]. We first wanted to document which of 
the 23 protein-coding zDHHC genes were expressed in 
MEFs and whether their expression was altered by DNA 
damage. Relative quantitative PCR analysis showed that 
MEFs expressed 20 zDHHC genes (Fig.  1). The mRNA 
for zDHHC19, 22 and 23 was not detectable in MEFs. 
However, they were found in mouse retina tissues (data 
not shown). We then treated MEFs with Dox, a chemo-
therapeutic drug that generates double-stranded and sin-
gle-stranded DNA breaks [29], and analyzed the mRNA 
levels of the zDHHC genes. Only zDHHC11, 17, 20 and 
24 mRNA showed increase of about twofold, while the rest 
exhibited no significant change. The expression of a wide 
spectrum of PATs in primary MEFs suggests that protein 
palmitoylation may play important roles in these cells.
Impaired DNA damage‑induced p53 activation in the 
presence of 2BP
We then wanted to study the possible roles of protein 
palmitoylation in DNA damage response. Since it was 
unfeasible to simultaneously silence most of the PATs 
with interference RNA, we used 2BP, a substrate analog 
inhibitor that had been widely used to block PAT activ-
ity [30–32]. Although it may have activities other than 
palmitoylation inhibition [26], we have shown that 2BP 
at the concentrations of 50  μM and above was able to 
inhibit total PAT activities in cultured cells [12, 33]. 
Indeed, reduced protein palmitoylation was observed in 
MEFs in the presence of 50  μM 2BP (Additional file  1: 
Figure S1). Additionally, 2BP showed very modest effects 
on the expression of a few zDHHC genes (Additional 
file 1: Figure S2).
Western blot analysis showed that Dox-induced 
increase in the protein levels of p53, phosphorylation 
of p53 at Ser15, and the protein levels of p21 and Bax, 
targets of p53, were inhibited in the presence of 2BP 
(Fig.  2a). While Dox induced a near fivefold increase of 
phosphorylated p53 in normal MEFs by 24 h, the increase 
was only 2.5-fold or none in cells with 50 and 100  μM 
2BP pre-treatment, respectively.
To further confirm these findings, we analyzed 
mRNA levels of p21 (Cdkn1a), Bax, and Puma (Bbc3) 
using relative quantitative PCR. We found that Dox 
treatment increased the mRNA levels of p21 and Bax 
but not Puma in MEFs (Fig.  2b). 2BP significantly 
inhibited the induction of p21 and Bax expression 
at the mRNA levels in response to Dox treatment 
(Fig.  2b). Since one of the main functions of 2BP was 
to inhibit PATs, these results suggest that protein pal-
mitoylation is required for the optimal induction of 
p53 target genes.
Impaired DNA damage‑induced Atm activation in the 
presence of 2BP
The induction and activation of p53 is dependent on Atm 
activation in response to double-stranded DNA breaks. 
We found decreased activation of Atm in primary MEFs, 
justified by decreased Atm phosphorylation on Ser1981 
(Fig.  3a, b) in the presence of 2BP. Although Ser1981 
phosphorylation is not required for Atm activation 
in vivo, it is an autophosphorylation commonly used as 
an indication of Atm activation [22]. Moreover, we found 
that 2BP also impeded DNA damage-induced Smad1 
activation (Fig.  3c), another cellular event that requires 
Atm activation [24].
Page 4 of 11Cao et al. BMC Molecular Biol  (2016) 17:12 
Impaired DNA damage foci formation in the presence 
of 2BP
We also looked at the formation of DNA damage foci 
in the presence of 2BP. In normal MEFs, Dox treatment 
induced DNA damage foci positive for γH2AX, TopBP1, 
and Brca1, which are believed to be signal propagation 
centers as well as DNA repair centers (Fig. 4a, b). In 2BP-
treated cells, the number of foci positive for γH2AX was 
higher than those in controls, especially at 8 and 16  h 
after Dox treatment. These results suggest that 2BP inter-
feres with the assembly/disassembly of the DNA damage 
foci or the DNA repair process.
Impaired DNA damage‑induced cell cycle arrest in the 
presence of 2BP
DNA damage eventually induces apoptosis or cell cycle 
arrest. Since 2BP compromised Atm activation and p53 
induction and activation, we suspected that 2BP might 
affect Dox-induced cell cycle arrest and apoptosis. Cell 
cycle arrest was analyzed by flow cytometry (Fig.  5a). 
Dox treatment led to an accumulation of cells in the 
G2/M phase, a decrease in G1 phase cells, and a mod-
est decrease in S phase cells in wild type MEFs. 2BP 
pre-treatment impeded Dox-induced increase in the per-
centage of cells arrested in the G2/M phase compared to 
control cells, without altering the percentage of S phase 
cells (Fig.  5b). These results suggest that protein palmi-
toylation is required for proper G2/M cell cycle arrest 
in DNA damage response. However, we found that 2BP 
showed some toxicity to MEFs at the doses used to inhibit 
protein palmitoylation, which may reflect a requirement 
for protein palmitoylation for cell survival, and the com-
bination of 2BP and Dox caused more cell death (Addi-
tional file  1: Figure S3). This prevented us from further 
Table 1 The primer sequences used in relative quantitative PCR
The accession number was obtained from NCBI nucleotide sequence database
Refseq gene Accession number Forward primer (5′‑3′) Reverse primer (5′‑3′) Amplicon size
Gapdh NM_008084 TGACCTCAACTACATGGTCTACA CTTCCCATTCTCGGCCTTG 85
Actb NM_007393 GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT 154
Zdhhc1 NM_175160 ATGAACATCTGCAACAAACCCT GCTCCATCCATTCCTTCGAGAG 126
Zdhhc2 NM_178395 TGCTGGGCTGGTCCTACTAC TGATAAGCCATGAGGCACAA 94
Zdhhc3 NM_178395 ATCCCCACCCATCACTTCC CTCGGATAAACCACATGGCTC 112
Zdhhc4 NM_026917 TTACCTAGATGACGTGGGGC AAACGATGACAAAGCCCAGT 110
Zdhhc5 NM_028379 CCGCCATATTTCTAGTGGGA TTGCATTGTAAATGGGCACT 99
Zdhhc6 NM_144887 GAGTAAGAGGGTGGTTTCCTAGA GCTGGATCTGAGTCACCATCAC 67
Zdhhc7 NM_025883 CACCAGGAGCCTCAGCACT AGCATCATGGGAGCACTTGT 110
Zdhhc8 NM_133967 GGTTGGTTCCAGCACACTCT AGAGGAAGAGGATGCCATTG 98
Zdhhc9 NM_172151 GGGCATCTTCTACCTGACCC AGACAGCTGAACAGCCAGGT 91
zdhhc11 NM_027704 CTGACACCAATGTCCGACTCA CGCGGTAACCTCACACAGG 116
Zdhhc12 NM_025428 GGGAATCACTCTGGTGCTCT CCCCTTGCTCTTCCCATT 104
Zdhhc13 NM_028031 GAGGCGTGCTTGGAGAGC CTGGAACGTGGGAGCCAT 129
Zdhhc14 NM_146073 CGGCGTCTTCTACCTGACTC GATGGCAGGGGTGATCTTCT 100
Zdhhc15 NM_175358 TGCCAGTGCTCGTTATTGTC AACTTTTTCCGCTGGACTCA 98
Zdhhc16 NM_023740 TACAGCTGCCAGCCTTTCC CCCAACAGCAGACTTCGC 115
zdhhc17 NM_172554 GCGGGAGGAGGGATTTAACAC CCCGTTTCGGTCTCGTACTC 63
zdhhc18 NM_001017968 TCAACGGGCAGACAGTGAAAC GAAGCGGTAGTTCCGTCTCC 158
Zdhhc19 NM_199309 TGTGACACTTGTGAAGGAACC AAAAACAGCAGCAGCGTTACA 106
Zdhhc20 NM_029492 ACCTTTGTGGTCGTCTGGTC GCCACAAGGTAAACAACGGT 104
Zdhhc21 NM_026647 GCTGCTTACTTGCTACGCAC CTCATGGCGAACAACAAAGA 100
Zdhhc22 NM_001080943 CGGCTGCTCAACGTGGTAG CCAGGACGTAATTGCCCAGG 190
Zdhhc23 NM_001007460 GGCTGCCTGTTTGTGTGATTG CCGTGATTCTTTCGCAAGTCTC 98
Zdhhc24 NM_027476 ACAGTGGCTCTCCTGCTGTT CACACGTGTCCACCACAAA 94
Zdhhc25 NM_027306 TTGGACTTACCTCGACCCAC ATAGGGGCAGGTAGGGACAC 109
Cdkn1a(p21) NM_007669 TCTCAGTGTTGAATACCGTGGG TAAGGGTAGACAGTCCAGACCA 115
Bax NM_007527 TGAAGACAGGGGCCTTTTTG AATTCGCCGGAGACACTCG 140
Bbc3(Puma) NM_133234 GCCCAGCCTGTAAGATACTGT CCTTACAGGTAGTGCCAGATGC 187
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testing the role of 2BP-suppressed p53 activation in DNA 
damage-induced apoptosis.
DHHC16 deficiency impaired the activation of Atm‑p53
We have previously reported the identification of one 
of the PATs, encoded by zDHHC16 gene. This pro-
tein, Aph2, was originally identified as a c-Abl inter-
acting protein (Abl-philin2) [34]. c-Abl is involved in 
DNA damage response. In particular, it is required for 
Atm-p53 activation [35–38]. Biochemical and genetic 
studies have shown that at least one protein, phos-
pholamban, a cardiac muscle specific protein, was 
palmitoylated by Aph2 [12]. In addition, MEFs over-
express zDHHC16 also showed increased total pro-
tein palmitoylation (Additional file  1: Figure S4a). 
Although Dox did not affect the expression of DHHC16 
at the mRNA level (Additional file  1: Figure S2), Dox 
induced nuclear translocation of ectopically-expressed 
DHHC16 (Additional file 1: Figure S4b). We have tried 
to raise anti-DHHC16 antibodies but those antibodies 
could not recognize endogenous DHHC16. This could 
be due to the fact that DHHC16 is a membrane protein. 
The lack of anti-DHHC16 antibodies prevents us to 
study the expression, localization, and modification of 
endogenous DHHC16 at the moment. To test whether 
DHHC16 also plays a role in DDR, we treated primary 
MEFs deficient for zDHHC16 gene with Dox for differ-
ent periods of time. Western blot analysis revealed that 
zDHHC16 deficiency, like inhibition of PATs with 2BP, 
compromised the activation of Atm and the induction 
of p53 and its target protein p21 (Fig. 6a–c).
DHHC16 deficiency impaired DNA damage foci formation 
and cell death
We next examined DNA damage foci formation in 
zDHHC16 deficient MEFs. Dox-treated zDHHC16−/− 
MEFs showed similar patterns of foci formation as the 
2BP-treated wild type MEFs. The number of TopBP1 
or Brca1 positive foci in zDHHC16−/− MEFs was sig-
nificantly higher than that in wild type cells (Fig. 7a–d). 
We also tested DNA damage-induced cell cycle arrest 
and apoptosis in zDHHC16−/− and wild type MEFs. 
We found that Dox-induced G2/M cell cycle arrest in 
Aph2−/− MEFs were not significantly different from 
those in wild type MEFs (data not shown). However, 
zDHHC16−/− MEFs showed a modest increase in cell 
survival compared to wild type MEFs (Fig.  7e). These 
results suggest that zDHHC16 plays a role in DNA dam-
age-induced cell death.
Discussion
In this study, we showed that 2BP impaired Dox-induced 
DNA damage response, in particular the activation of 
the Atm-p53 pathway, and led to disrupted activation of 
the cell cycle checkpoint and DNA damage foci dynam-
ics in primary MEFs. Since 2BP is a general PAT inhibi-
tor which also binds palmitoylated proteins, we further 
showed that the defective DNA damage responses 
Fig. 1 zDHHC gene expression in primary MEFs. The expression of each gene in primary MEFs without Dox treatment was set as 1 (as indicated 
by the horizontal line) and used to calculate the relative abundance of the same gene under Dox treatment for 8 and 16 h respectively. Gapdh and 
β‑actin gene expression were used as internal controls and similar results were obtained. Error bars represented standard error means of repeated 
experiments. Notice that zDHHC10 is a pseudogene and the expression of zDHHC19, 22 and 23 genes were not detected
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observed in 2BP-treated cells were largely replicated in 
MEFs deficient for zDHHC16, one of the 23 palmitoyl-
transferases. Collectively our data suggested that pro-
tein palmitoylation carried out by PATs, in particular 
by zDHHC16, plays an important role in DNA damage 
response. Since DDR, in particular the Atm-p53 path-
way, is the major tumor suppression scheme, our findings 
also provide a possible explanation on how some zDHHC 
proteins exert their tumor suppression activities [13].
Palmitoylation is a common protein post-translational 
modification [1, 3, 14]. This is also evident by the expres-
sion of a variety of zDHHC genes in primary MEFs. 
However, little is known about the specific in vivo func-
tions of each PAT. zDHHC16 knockout mice showed 
neonatal lethality with severe cardiac and ocular defects. 
It appears that one of the substrates of zDHHC16 protein 
in heart is phospholamban, which is largely responsible 
for cardiac defects observed in zDHHC16 knockout mice 
[12]. Here we found that cells deficient of zDHHC16 also 
had defective DNA damage response, a function that has 
not been previously ascribed to zDHHC16 or any other 
PATs.
How does zDHHC protein facilitate Atm activation? 
Since Atm is not known to be modified by palmitoylation, 
Fig. 2 Inhibition of palmitoylation by 2BP impaired DNA damage‑induced p53 up‑regulation and activation. a Western blot analysis showed that 
2BP pre‑treatment impeded the induction of p53 protein expression, p53 phosphorylation on Ser15, and p21 and Bax protein levels in response to 
Dox treatment. Primary MEFs were pre‑treated with 50 or 100 μM 2BP for 24 h and then stimulated with 1 μM of Dox for different periods of time as 
indicated. The protein levels of p53, p‑p53, p21, Bax, and actin were determined by Western blot analysis. b Relative quantitative PCR results showed 
that 2BP pre‑treatment impeded the induction of Bax and p21 (Cdkn1a) gene expression, but not much of Puma (Bbc3) gene expression. The cells 
were pre‑treated without (−2BP) or with 50 μM 2BP (+2BP) for 24 h and followed by 1 μM Dox treatment for 0, 8 and 16 h. The expression of each 
gene without 2BP and Dox treatment was set as 1 (as indicated by the horizontal line) and used to compare the expression of the same gene under 
different stimulated conditions. Error bars represented standard error mean of the repeated experiments. Asterisk denoted significant difference 
(p < 0.05) etween Dox alone and 2BP plus Dox treated samples
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zDHHC16 and other PATs likely regulate the protein(s) 
that affect Atm activation upon DNA damage. Atm 
activation requires MRN complex (a protein complex 
consisting of Mre11, Rad50 and Nbs1), DNA conforma-
tional change, and/or DNA breaks. The generally agreed 
major function of palmitoylation is to increase the hydro-
phobicity of the targeted protein, thus facilitate protein 
anchoring to membrane and subsequent interaction 
with other proteins [1, 2, 13]. Since most of the DNA 
damage foci proteins and signaling molecules are local-
ized in the nucleus, it is more likely that palmitoylation 
affects the stability and/or complex assembly of the pro-
teins that are involved in DNA damage response rather 
than their membrane association. One such candidate 
may be histone protein, which has been reported to be 
palmitoylated [39, 40]. Palmitoylation of histone proteins 
may affect the remodeling of chromatin structures, which 
may in turn affect DNA damage foci formation and/or 
DNA conformation, eventually lead to alteration of Atm 
activation and DNA repair [21, 41]. Whether histone 
proteins are substrates of zDHHC16 warrants further 
investigation.
Alternatively, zDHHC16 protein may regulate DNA 
damage response through c-Abl. zDHHC16 was originally 
identified as a c-Abl interacting protein, which was also 
named Aph2 [34]. c-Abl is activated in Atm-dependent 
manner in response to DNA damage. Activated c-Abl 
helps to up-regulate p53 and p73 expression and also 
plays a positive role in maximal Atm/Atr activation [35–
37]. zDHHC16 seems to have a similar role as c-Abl in 
Atm activation in DNA damage response, yet c-Abl is not 
a substrate of zDHHC16 [12]. It is possible that zDHHC16 
may regulate DDR via c-Abl in a palmitoylation-inde-
pendent manner. Further exploration on the nature of 
interaction between zDHHC16 and c-Abl will help under-
stand how zDHHC16 affects DNA damage response.
Fig. 3 Inhibition of palmitoylation impaired DNA damage‑induced Atm activation. a Western blot analysis showed that inhibition of palmitoyl‑
transferase by 2BP led to a decrease in Atm phosphorylation on S1981. Primary MEFs were pre‑treated with 50 μM 2BP for 24 h followed by 1 μM 
Dox for different periods of time. b Quantitation of phosphorylated Atm at Ser1981 after being normalized to total Atm. Asterisk denoted significant 
difference (p < 0.05) between control and 2BP treated cells. c 2BP compromised DNA damage‑induced Smad1 activation. Cells were treated the 
same as described in 3A and probed for total and phosphorylated Smad1/5/8 and p53
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Conclusions
In summary, this study, for the first time, uncovered a 
critical role for protein palmitoylation and more specifi-
cally zDHHC16 in DNA damage response. These find-
ings advance our understanding of the regulation of 
DNA damage response and provide a possible explana-
tion on how protein palmitoylation is involved in cancer 
development. Moreover, our results expand the role of 
palmitoylation on cellular activities and calls for further 
research on palmitoylated nuclear proteins.
Fig. 4 Inhibition of palmitoylation impaired assembly/disassembly of DNA damage foci. Primary MEFs grown on coverslips were pre‑treated with 
50 μM 2BP for 24 h and then treated with 1 μM Dox for different periods of time. The cells were then fixed and immune‑stained for H2AX using 
Texas‑red conjugated secondary antibodies (a). b Averaged number of foci per cell from multiple repeated experiments and multiple cells per 
experiment. Asterisk denoted significant difference (p < 0.05) between compared groups
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Fig. 5 Inhibition of palmitoylation impaired DNA damage‑induced cell cycle arrest at G2/M phase. Primary MEFs were pre‑treated with 50 μM 2BP 
for 24 h and then treated with 1 μM of Dox for 24 h. The cells were harvested, fixed, stained with PI, and analyzed by flow cytometry. a Representa‑
tive micrographs of flow cytometry analysis. b Averaged data from multiple experiments. The total number of cells analyzed was set as 100 % and 
cells at different phase were calculated accordingly
Fig. 6 zDHHC16 deficiency impaired DNA damage‑induced Atm‑p53 activation. a Western blot analysis showed reduced Atm phosphorylation at 
S1981 in zDHHC16−/− MEFs. Primary zDHHC16−/− MEFs were isolated from zDHHC16−/− mice and treated with 1 μM Dox for different periods of 
time as indicated. b Quantitation data on p‑Atm. Asterisk denoted significant difference (p < 0.05) between control and 2BP treated cells. c Activa‑
tion and induction of p53 and p21. Cells were treated the same as above
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